Ledger entry · candidate
Ertugliflozin → Inability to afford medication — Audit-grade candidate (class scan)
Drug: ertugliflozin · AE: Inability to afford medication
Discovered via class scan of SGLT2 inhibitors. PRR = 42.64, n = 25 cases.
Disproportionality
- PRR: 42.638990269429605
- Yates χ2: n/a
- Cases (case-drug + AE): n = 25
- Verdict:
PASSES_ALL_GATES — PRR=42.64 (95% CI 28.91–62.89), n=25 cases; flagged for clinical expert review, NOT for external escalation without manual verification
Top reactions in cohort
| MedDRA PT | n |
|---|
| No reactions surfaced in cohort. |
Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.